knowledge -WSS

knowledge

author：leisure time 2025-09-02 22:22:43 - browse：61

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Eli Lilly expects to double planned employment in Boston center

focus

WSS

STAT Summit: Michael J. Fox on progress in Parkinson's research

STAT Summit: Biotech founders on deal

Male and female sex labels in research insufficient, scientists say

UCLA team creates talking throat patch for voice disorders

Amid AI frenzy, a top HHS official's quest to create safeguards

STAT Summit: GSK CEO on pharma giant's new direction

Wikipedia

knowledge

focus

23andMe had bad news about my health. I wish a person had delivered it

Readout Newsletter: CAR

Sports medicine is finally prioritizing gender equality

Male and female sex labels in research insufficient, scientists say

Sports medicine is finally prioritizing gender equality

RaDonda Vaught links Vanderbilt hospital issues to patient death

Duchenne breakthrough therapy leaves behind pioneering families

STAT Summit: GSK CEO on pharma giant's new direction

Cancer drug shortages should be causing more outrage

How to save health care price transparency rules

entertainment

Readout Newsletter: CAR

2023 STAT Wunderkinds: get to know the winners

The EU Joint Clinical Assessment needs to live up to its promise

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Hospital price transparency does save money, advocate argues

President Biden's budget: Here's what you might have missed

focus

focus

focus

hotspot